Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 2/20 | 0.36 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.34 |
| ▸ | RAPGEF4 | Q8WZA2 | 3/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PGK1 | P00558 | 1/20 | 0.32 |
| ▸ | PGK2 | P07205 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.32 |
| ▸ | CNR1 | P21554 | 2/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL172803 | 0.84 | TSHR (0.50) | IDO1PTGS2TSHRALDH1A1GAA | |
| SCHEMBL3790308 | 0.84 | TSHR (0.41) | IDO1PTGS2TSHRALDH1A1GAA | |
| SCHEMBL16956780 | 0.81 | FFAR4 (0.39) | NR3C1NR3C2PGRIDO1RAPGEF4 | |
| SCHEMBL271754 | 0.81 | ALDH1A1 (0.42) | NR3C1NR3C2PGRRAPGEF4PTGS2 | |
| SCHEMBL5490825 | 0.81 | PGK1 (0.44) | RAPGEF4PTGS2TSHRALDH1A1GAA | |
| SCHEMBL168174 | 0.81 | PGK1 (0.44) | RAPGEF4PTGS2TSHRALDH1A1GAA | |
| SCHEMBL14114133 | 0.80 | IDO1 (0.34) | NR3C1NR3C2PGRIDO1RAPGEF4 | |
| Ammonia Solution, Strong SCHEMBL5606944 | 0.78 | PGK1 (0.42) | RAPGEF4PTGS2TSHRALDH1A1GAA | |
| SCHEMBL14464883 | 0.78 | PNMT (0.46) | IDO1RAPGEF4NR1D1 | |
| SCHEMBL15712079 | 0.78 | RAPGEF4 (0.33) | NR3C1NR3C2PGRIDO1RAPGEF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1453792-B1 | AMINE 1,2- AND 1,3-DIOL COMPOUNDS AND THEIR USE FOR TREATMENT OF ALZHEIMER'S DISEASE | ELAN PHARM INC (US) | 2007-04-18 | — | — | EP | claimed |
| EP-1453792-A1 | AMINE 1,2- AND 1,3-DIOL COMPOUNDS AND THEIR USE FOR TREATMENT OF ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-09-08 | — | — | EP | claimed |
| EP-1448200-A2 | (4-PHENYL)PIPERIDIN-3-YL-PHENYLCARBOXYLATE DERIVATIVES AND RELATED COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-08-25 | — | — | EP | claimed |
| US-20040039064-A1 | Amine 1,2- and 1,3-diol compounds | PHARMACIA & UPJOHN COMPANY LLC | 2004-02-26 | — | — | US | claimed |
| US-20040034031-A1 | 3,4-Disubstituted, 3,5-disubstituted and 3,4,5-substituted piperidines | ELAN PHARMACEUTICALS, INC. | 2004-02-19 | — | — | US | claimed |
| WO-2003043975-A1 | AMINE 1,2- AND 1,3-DIOL COMPOUNDS AND THEIR USE FOR TREATMENT OF ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2003-05-30 | — | — | WO | claimed |
| WO-2003043987-A2 | (4-PHENYL) PIPERIDIN-3-YL-PHENYLCARBOXYLATE DERIVATIVES AND RELATED COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2003-05-30 | — | — | WO | claimed |
| EP-4065564-B1 | [ (1,5-DIPHENYL-1H-1,2,4-TRIAZOL-3-YL) OXY ] ACETIC ACID DERIVATIVES AND SALTS THEREOF, USEFUL OR CULTIVATING AGENTS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS SAFENERS | BAYER AG (DE) | 2023-07-26 | — | — | EP | disclosed |
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| US-20220251117-A1 | PROTEASOME INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2022-08-11 | — | — | US | disclosed |
| US-11028068-B2 | Somatostatin modulators and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2021-06-08 | — | — | US | disclosed |
| US-20200207737-A1 | SOMATASTATIN MODULATORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-07-02 | — | — | US | disclosed |
| US-10590076-B2 | Hepatitis B capsid assembly modulators | VenatoRx Pharmaceuticals, Inc. (US) | 2020-03-17 | — | — | US | disclosed |
| EP-1453792-A1 | AMINE 1,2- AND 1,3-DIOL COMPOUNDS AND THEIR USE FOR TREATMENT OF ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-09-08 | — | — | EP | disclosed |
| EP-1448200-A2 | (4-PHENYL)PIPERIDIN-3-YL-PHENYLCARBOXYLATE DERIVATIVES AND RELATED COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-08-25 | — | — | EP | disclosed |
| US-20040039064-A1 | Amine 1,2- and 1,3-diol compounds | PHARMACIA & UPJOHN COMPANY LLC | 2004-02-26 | — | — | US | disclosed |
| US-20040034031-A1 | 3,4-Disubstituted, 3,5-disubstituted and 3,4,5-substituted piperidines | ELAN PHARMACEUTICALS, INC. | 2004-02-19 | — | — | US | disclosed |
| WO-2003043975-A1 | AMINE 1,2- AND 1,3-DIOL COMPOUNDS AND THEIR USE FOR TREATMENT OF ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2003-05-30 | — | — | WO | disclosed |
| WO-2003043987-A2 | (4-PHENYL) PIPERIDIN-3-YL-PHENYLCARBOXYLATE DERIVATIVES AND RELATED COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2003-05-30 | — | — | WO | disclosed |
| US-4538003-A | TREATMENT WITH MAGNESIUM OR ZINC ORGANOMETALLIC REAGENTS IN PRESENE OF A NICKEL BIDENTATE OR TRIDENTATE PHOSPHOROUS LIGAND | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1985-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039064-A1 | Amine 1,2- and 1,3-diol compounds | BACE1, BACE2, APP | NR3C1 869/4885NR3C2 1258/4885PGR 1966/4885 |
| US-10590076-B2 | Hepatitis B capsid assembly modulators | HAVCR2, COPB1, HDLBP | NR3C1 4282/4885NR3C2 4498/4885PGR 3824/4885 |
| US-20200207737-A1 | SOMATASTATIN MODULATORS AND USES THEREOF | SSTR5, SSTR2, SSTR4 | NR3C1 1659/4885NR3C2 392/4885PGR 2948/4885 |
| US-20040034031-A1 | 3,4-Disubstituted, 3,5-disubstituted and 3,4,5-substituted piperidines | BACE1, APP, BACE2 | NR3C1 4198/4885NR3C2 4060/4885PGR 3995/4885 |
| US-20220251117-A1 | PROTEASOME INHIBITORS | PSMB5, PSMG3, PSMB1 | NR3C1 2126/4885NR3C2 2705/4885PGR 2046/4885 |
| US-11028068-B2 | Somatostatin modulators and uses thereof | SSTR5, SSTR2, SSTR4 | NR3C1 327/4885NR3C2 184/4885PGR 582/4885 |
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | TEAD1, TEAD4, TEAD2 | NR3C1 883/4885NR3C2 996/4885PGR 4205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.